Neglected Tropical Disease Elimination — 2026-09-25
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
This week's NTD news is thin on campaign headlines but rich on diagnostics and Americas momentum: the NTD diagnostics market is forecast to nearly double by 2035, and PAHO has launched "Trachoma Plus" training in Guyana on September 22, 2026, to advance the regional elimination agenda. Meanwhile, pressure is mounting over $1.3 billion in unspent US global health funds that must be released by September 30.
Neglected Tropical Disease Elimination — 2026-09-25
Top developments
PAHO launches Trachoma Plus training in Guyana
On September 22, 2026, PAHO/WHO, the Guyana Ministry of Health and the Government of Canada began a series of training workshops covering trachoma, health service outreach, and molecular diagnostics. The initiative strengthens the Americas' pipeline toward trachoma validation, following Paraguay's August technical mission toward its own elimination validation.
NTD diagnostics market set to reach $11.3 billion
Published September 23, 2026, a market forecast projects the neglected tropical diseases diagnostics market growing from USD 7.42 billion in 2025 to USD 11.30 billion by 2035, a 4.3% CAGR. The growth reflects elimination programs demanding proof of elimination — surveillance-grade diagnostics — rather than simple case detection. This matters for trachoma, lymphatic filariasis and Guyana worm programs that must demonstrate zero transmission for certification.
$1.3 billion in unspent US health funds must be released by September 30
Reported roughly a week ago, The Independent reports that $1.3 billion in US health funding for tuberculosis, malaria, HIV and maternal health left unspent by the Trump administration "could lead to 150,000 preventable deaths," with a spending deadline of September 30. Any broadly weakened global health delivery platform compounds existing NTD funding gaps across Africa, where WHO AFRO has already flagged a funding crisis threatening elimination campaigns.
Local view
No recent local-language data available for this section.
Context & numbers
- NTD diagnostics market: USD 7.42 billion (2025) → USD 11.30 billion (2035), 4.3% CAGR.
- 64 countries have now eliminated at least one NTD (as of mid-2026), per the END Fund; 22 African countries had eliminated at least one NTD by December 2025 per WHO AFRO.
- Background for the Americas push: trachoma has been eliminated as a public health problem throughout WHO's South-East Asia Region following Timor-Leste's validation.
On the radar
- September 30, 2026: deadline for release of US government global health funds; watch whether NTD-adjacent programs are affected.
- DNDi expects results in Q3 2026 from its DNDI-6899 visceral leishmaniasis Phase I study (concluding May 2026) — a key pipeline signal for kala-azar elimination in Africa.
- Rumor flag: continued US aid cut reports suggest further disruption to donated-drug supply chains (ivermectin, azithromycin, albendazole) — unconfirmed; monitor for formal announcements.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
